

Precision Gestational Diabetes Treatment: Systematic review and Meta-analyses

Jamie L Benham^{*1}, Véronique Gingras^{*2,3}, Niamh-Maire McLennan^{*4}, Jasper Most^{*5}, Jennifer M Yamamoto^{*6}, Catherine E Aiken^{*7,8}, Susan E Ozanne^{**9}, Reynolds RM^{**4,10} on behalf of ADA/EASD PMDI

*These authors contributed equally

** These authors contributed equally

¹Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada

²Department of Nutrition, Université de Montréal, Montreal, Quebec, Canada

³Research Center, Sainte-Justine University Hospital Center, Montreal, Quebec, Canada

⁴MRC Centre for Reproductive Health, Queens's Medical Research Institute, University of Edinburgh, Edinburgh, UK

⁵Department of Orthopedics, Zuyderland Medical Center, Sittard-Geleen, The Netherlands

⁶Internal Medicine, University of Manitoba, Winnipeg, MB, Canada

⁷Department of Obstetrics and Gynaecology, the Rosie Hospital, Cambridge, UK

⁸NIHR Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK

⁹University of Cambridges Metabolic Research Laboratories and MRC Metabolic Diseases Unit, University of Cambridge, Wellcome-MRC Institute of Metabolic Science, Cambridge, UK

¹⁰Centre for Cardiovascular Science, Queens's Medical Research Institute, University of Edinburgh, Edinburgh, UK

Corresponding author: Rebecca M Reynolds
Centre for Cardiovascular Science
Queen's Medical Research Institute
47 Little France Crescent
Edinburgh EH16 4TJ
Email: r.reynolds@ed.ac.uk
ORCID ID: 0000-0001-6226-8270

ABSTRACT

We hypothesized that a precision medicine approach could be a tool for risk-stratification of women to streamline successful GDM management. With the relatively short timeframe available to treat GDM, commencing effective therapy earlier, with more rapid normalization of hyperglycaemia, could have benefits for both mother and fetus. We conducted two systematic reviews, to identify precision markers that may predict effective lifestyle and pharmacological interventions. There were a paucity of studies examining precision lifestyle-based interventions for GDM highlighting the pressing need for further research in this area. We found a number of precision markers identified from routine clinical measures that may enable earlier identification of those requiring escalation of pharmacological therapy. Whether there are other sensitive markers that could be identified using more complex individual-level data, such as 'omics', and if these can be implemented in clinical practice remains unknown. These will be important to consider in future studies.

INTRODUCTION

Gestational diabetes (GDM) is the most common pregnancy complication, occurring in 3% to 25% of pregnancies globally¹. GDM is associated with significant short- and long-term risks to both mothers and babies, including adverse perinatal outcomes, future obesity, type 2 diabetes and cardiovascular disease¹⁻³. The landmark Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) demonstrated that effective treatment of GDM reduces serious perinatal morbidity⁴.

Current treatment guidelines for management of GDM assume homogeneous treatment requirements and responses, despite the known heterogeneity of GDM aetiology⁵⁻⁸. Standard care includes diet and lifestyle advice at a multi-disciplinary clinic, home blood glucose monitoring at least four times per day, clinic reviews every two to four weeks, and then progression to pharmacological treatment with metformin, glyburide and/or insulin if glucose targets are not met. Around a third of women cannot maintain euglycaemia with lifestyle measures alone and require treatment escalation to a pharmacological agent³. Yet current treatment pathways often take 4-8 weeks to achieve glucose targets. This delay resulting in continued exposure to hyperglycaemia poses a significant risk of accelerated fetal growth^{9,10}. Previous research has suggested that maternal characteristics including body mass index (BMI) ≥ 30 kg/m², family history of type 2 diabetes, prior history of GDM and higher glycated haemoglobin (HbA1c) increase the likelihood of need for insulin treatment in GDM¹¹, indicating the potential for risk-stratification of women to streamline successful GDM management. There is emerging evidence that precision biomarkers predict treatment response in type 2 diabetes, which has similar heterogeneity to GDM^{12,13} and thus gives rationale to investigate whether a similar precision approach could be successful in optimizing outcomes in GDM.

To address this knowledge gap, we conducted two systematic reviews of the available evidence for precision markers of GDM treatment. We aimed to determine (i) which precision diet and lifestyle interventions delivered in addition to standard of care enable achievement of glucose targets with lifestyle measures alone, (ii) which patient-level characteristics or factors predict whether glucose targets can be achieved in women treated with diet and lifestyle alone, and in women receiving oral agents for treatment of GDM.

The Precision Medicine in Diabetes Initiative (PMDI) was established in 2018 by the American Diabetes Association (ADA) in partnership with the European Association for the Study of Diabetes (EASD). The ADA/EASD PMDI includes global thought leaders in precision diabetes medicine who are working to address the burgeoning need for better diabetes prevention and care through precision medicine¹⁴. This systematic review is written on behalf of the ADA/EASD PMDI as part of a comprehensive evidence evaluation in support of the 2nd International Consensus Report on Precision Diabetes Medicine¹⁵.

METHODS

The systematic reviews and meta-analyses were performed as outlined *a priori* in the registered protocols (PROSPERO registration IDs CRD42022299288 and CRD42022299402). The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines¹⁶ were followed. Ethical approval was not required as these were secondary studies using published data.

Literature Searches, Search Strategies and Eligibility Criteria

Search strategies for both reviews were developed based on relevant keywords in partnership with scientific librarians (see Supplementary Text S1 for full search strategies). We searched two databases (MEDLINE and EMBASE) for studies published from inception until January 1st, 2022. We also scanned the references of included manuscripts for inclusion as well as relevant reviews and meta-analyses published within the past two years for additional citations.

For both systematic reviews we included studies (randomized or non-randomized trials, and observational studies) published in English and including women ≥ 16 years old with diagnosed GDM, as defined by the study authors. For the first systematic review (precision diet and lifestyle interventions), we included studies with any behavioural intervention (e.g., exercise, diet, motivational interviewing) over and above standard care compared to a control group receiving standard care only. For the second systematic review (precision predictors of need for pharmacological interventions to achieve glucose targets), we included studies using pharmacological therapy to treat GDM (e.g., insulin, metformin, sulphonylurea) compared to a control group receiving standard care with diet and lifestyle measures, or taking oral agents before progression to insulin. For both reviews, we included any relevant reported outcomes; maternal (e.g., treatment adherence, hypertensive disorders of pregnancy, gestational weight gain, mode of birth), neonatal (e.g., birthweight, macrosomia, shoulder dystocia, preterm birth, neonatal hypoglycaemia, neonatal death), cost efficiency or acceptability. We excluded studies with a total sample size < 50 participants to ensure sufficient data to interpret the effect of precision markers. We also excluded studies published before or during 2004, in order to consider studies with standard care similar to ACHOIS⁴.

Study selection and data extraction

The results of our two searches were imported separately into Covidence software (Veritas Health Innovation, Australia, available at www.covidence.org) and duplicates were removed. Two reviewers independently reviewed identified studies. First, they screened titles and abstracts of all references identified from the initial search. In a second step, the full-text articles of potentially relevant publications were scrutinized in detail and inclusion criteria were applied to select eligible articles. Reason for exclusion at the full text review stage was documented. Disagreement between reviewers was resolved through consensus by discussion with the group of authors.

Two reviewers independently extracted relevant information from each eligible study, using a pre-specified standardized extraction form. Any disagreement between reviewers was resolved as outlined above.

Data extracted included first author name, year of publication, country, study design, type and details of the intervention when applicable, number of cases/controls or cohort groups, total number of participants and diagnostic criteria used for GDM. Extracted data elements also included outcomes measures, size of the association (Odds Ratio (OR), Relative Risk (RR) or Hazard Ratio (HR)) with corresponding 95% Confidence Interval (CI) and factors adjusted for, confounding factors taken into consideration and methods used to control covariates. We prioritized adjusted values where both raw and adjusted data were available. Details of precision markers (mean (standard deviation) for continuous variables or N (%) for categorical variables) including BMI (pre-pregnancy or during pregnancy), ethnicity, age, smoking status, comorbidities, parity, glycaemic variables (e.g., oral glucose tolerance test (OGTT) diagnostic values, HbA1c), timing of GDM diagnosis, history of diabetes or of GDM, and season were also extracted.

Quality assessment (risk of bias and GRADE assessments)

We first assessed the quality and risk of bias of each individual study using the Joanna Briggs Institute (JBI) critical appraisal tools¹⁷. A Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach was then used to review the total evidence for each precision marker, and the quality of the included studies to assign a GRADE certainty to this body of evidence (high, moderate, low and/or very low)¹⁸. Quality assessment was performed in duplicate and conflicts were resolved through consensus.

Statistical analysis

Where possible, meta-analyses were conducted using random effects models for each precision marker available. The pooled effect size (mean difference for continuous outcomes and ORs for categorical outcomes) with the corresponding 95% CI were computed. The heterogeneity of the studies was quantified using I^2 statistics, where $I^2 > 50\%$ represents moderate and $I^2 > 75\%$ represents substantial heterogeneity across studies. Publication bias was assessed with visual assessment of funnel plots. Statistical analyses were performed using Review Manager software [RevMan, Version 5.4.1, The Cochrane Collaboration, Copenhagen, Denmark].

RESULTS

Study selection and study characteristics

PRISMA flow charts (Figures 1A and 1B) summarize both searches and study selection processes.

For the first systematic review (precision diet and lifestyle interventions), we identified 2 eligible studies (n=2,354 participants), which were randomized trials from USA and Singapore (Table 1A)^{19,20}.

For the second systematic review (precision predictors of need for pharmacological interventions to achieve target glucose levels), we identified 48 eligible studies (n=25,724 participants) (Table 1B)²¹⁻⁶⁸.

There were 34 studies (n=23,831 participants) where standard care with diet and lifestyle advice was not adequate to achieve target glucose levels. Of these, 29 studies (n=20,486) reported progression to insulin²¹⁻⁴⁹ and 5 (n=3,345) reported progression to any medication (metformin, glyburide and/or insulin)⁵⁰⁻⁵⁴.

There were 12 studies (n=1,669 participants) where treatment with oral agents was not adequate to achieve target glucose levels, and escalation to insulin was required. Initial treatment was with glyburide in 6 of these studies (n=527)⁵⁵⁻⁶⁰ and metformin in the other 6 studies (n=1142)⁶¹⁻⁶⁶.

A further 2 eligible studies reported maternal genetic predictors of need for supplementary insulin after glyburide (n=117 participants)⁶⁷ and maternal lipidome responses to metformin and insulin (n=217 participants)⁶⁸.

The majority of included studies were observational in design. Most studies reported outcomes of singleton pregnancies. The studies were from a range of geographical locations: Europe (Belgium, Finland, France, Italy, Netherlands, Poland, Portugal, Spain, Sweden), Switzerland, Middle East (Israel, Qatar, United Arab Emirates), Australasia (Australia, New Zealand), North America/Latin America (Canada, USA and Brazil) and Asia (China, Malaysia, Japan). There were

a range of approaches to GDM screening, choice of diagnostic test and diagnostic glucose thresholds.

Quality assessment

Study quality assessment is presented as an overall risk of bias for the studies included in the meta-analyses in Figure 2.1 and as a heat map for quality assessment for each included study in Figure 2.2. Most of the studies were rated as low risk of bias, as they adequately described how a diagnosis of GDM was assigned, defining inclusion and exclusion criteria, and reported the protocol for initiation of pharmacological therapy. Not all studies reported whether women received diet and lifestyle advice as standard care. Few studies reported whether the precision marker was measured in a valid and reliable way. Using the GRADE approach, the majority of precision markers were classified as having a low certainty of evidence with some classified as very low certainty (Tables 2 and 3). No publication bias (as ascertained by funnel plot analyses) was detected.

Synthesis of results

Precision diet and lifestyle interventions in GDM

Two studies examining different behavioural interventions were included in the first systematic review, so we present a narrative synthesis of the findings. Neither study examined whether a precision lifestyle intervention enabled achievement of glucose targets during pregnancy.

In one study¹⁹, the intervention was distribution of a tailored letter detailing gestational weight gain (GWG) recommendations (as defined by the Institute of Medicine). Receipt of this tailored letter increased the likelihood of meeting the end-of-pregnancy weight goal among women with normal pre-pregnancy BMI, but not among women with overweight or obese pre-pregnancy BMI. This study identified normal pre-pregnancy BMI as a precision marker for intervention success.

The second study²⁰ used a Web/Smart phone lifestyle coaching program. Pre-intervention excessive GWG was evaluated as a potential precision marker. There was no difference between study arms with respect to either excess GWG or absolute GWG by the end of pregnancy indicating that early GWG is not a useful precision marker with respect to this intervention.

Precision predictors of need for pharmacological interventions to achieve glucose targets in GDM

Of the 34 studies of predictors of need for medical therapy in addition to standard care with diet and lifestyle advice to achieve glucose targets, 23 studies (n=19,112 participants) were included in the meta-analysis^{21-23,25,26,31-36,38,40,41,43-46,48,50-53} and 11 studies (n=7158 participants) in the narrative synthesis^{24,27-30,37,39,42,47,49,54}.

Table 2 and Supplementary Figures 1.1-1.13 show that precision markers for GDM to be adequately managed with lifestyle measures without need for additional pharmacological therapy were lower maternal age, nulliparity, lower BMI, no previous history of GDM, lower HbA1c, fasting, 1 hour, 2 and 3 hour glucose, no family history of diabetes, later gestation of diagnosis of GDM and no macrosomia in previous pregnancies. There was a similar pattern for not smoking but this did not reach statistical significance.

Twelve studies (n=1669 participants) of predictors of need for supplemental insulin to achieve normoglycaemia following treatment with oral agents were included in the meta-analysis⁵⁵⁻⁶⁶.

Table 3 and Supplementary Figures 2.1-2.12 show that precision markers for achieving normoglycaemia with oral agents only were nulliparity, lower BMI, no previous history of GDM, lower HbA1c, fasting, 1 hour, and 2 hour glucose, later gestation of diagnosis of GDM and later gestation at initiation of the oral agent. In sensitivity analyses, there were no differences in the precision markers predicting response to metformin versus glyburide.

Similar findings were observed in the 11 studies (n=7158 participants) that were not included in the meta-analysis^{24,27-30,37,39,42,47,49,54} (Supplementary Table 1). Additional precision markers including fetal sex²⁸, ethnicity^{30,47}, and season of birth³⁷ were evaluated but there was insufficient data to draw conclusions.

There was a paucity of data in examining other precision markers with only weak evidence that the maternal lipidome⁶⁸ or genetics⁶⁷ hold potential as precision markers of need for pharmacological treatment (Supplementary Table 1).

DISCUSSION

As the factors contributing to development of GDM are heterogeneous⁵⁻⁸, it is plausible that the most effective treatment strategies may also be variable. A precision medicine approach resulting in more rapid normalization of hyperglycaemia could have substantial benefits for both mother and fetus. By synthesizing the evidence from two systematic reviews, we sought to identify key precision markers that may predict effective lifestyle and pharmacological interventions. There were a paucity of studies examining precision lifestyle-based interventions for GDM highlighting the pressing need for further research in this area. However, we found a number of precision markers to enable earlier identification of those requiring escalation of pharmacological therapy. These included characteristics such as BMI, that are easily and routinely measured in clinical practice, and thus have potential to be integrated into prediction models with the aim of achieving rapid glycaemic control. With the relatively short timeframe available to treat GDM, commencing effective therapy earlier, and thus reducing excess fetal growth, is an important target to improve outcomes. Basing treatment decisions closely on precision markers could also avoid over-medicalisation of women who are likely to achieve glucose targets with dietary counselling alone.

In our first systematic review we identified only two studies addressing precision markers in lifestyle-based interventions for GDM, over and above standard care^{19,20}. In both studies, precision markers were examined as secondary analyses of the trials and only two precision markers (BMI and GWG) were assessed; it is thus not possible to conclusively identify any precision marker in lifestyle-based interventions for GDM. This gap in the literature highlights the need for more research, as also echoed by patients and healthcare professionals participating in the 2020 James Lind Alliance (JLA) Priority Setting Partnership (PSP)⁶⁹.

Our second systematic review extends the observations of a previous systematic review reporting maternal characteristics associated with the need for insulin treatment in GDM¹¹. We identified a number of additional precision markers of successful GDM treatment with lifestyle measures alone, without need for additional pharmacological therapy. The same set of predictors identified women requiring additional insulin after treatment with glyburide as with metformin, despite their different mechanisms of action. However the numbers of women included in most studies were relatively low and most studies with data in relation to glyburide failure were over 10 years old^{55,56,58-60}. We acknowledge that there are also differences in diagnostic criteria, clinical practices, and preferences for choice of which drug to start as first pharmacological agent in various global regions which may limit the generalizability of our findings.

Notably, many of the identified precision markers are routinely measured in clinical practice and so could be incorporated into prediction models of need for pharmacological treatment^{70,71}. By identifying those who require escalation of pharmacological therapy earlier, better allocation of resources can be achieved. Additionally, some of the precision markers identified, such as BMI, are potentially modifiable. This raises the question of how women can be helped to better prepare for pregnancy⁷². Implementing interventions prior to pregnancy could help understand if these precision markers are on the causal pathway, thus providing an opportunity for prevention and improving health outcomes.

Importantly, there was a lack of data on other potential precision treatment biomarkers, with only two eligible low quality studies reporting maternal genetic and metabolomic findings^{67,68}. In the non-pregnancy literature, efficacy of dietary interventions has been reported to differ for patients with distinct metabolic profiles, for example high fasting glucose vs high fasting insulin, or insulin resistance vs low insulin secretion⁷³⁻⁷⁵. More recent evidence from appropriately designed, prospective dietary intervention studies has confirmed that dietary interventions tailored towards specific metabolic profiles have more beneficial effects than interventions not specifically designed towards a patient's metabolic profile⁷⁶⁻⁷⁹. Ongoing studies such as the Westlake Precision Birth Cohort (WeBirth) in China (NCT04060056) and the USA Hoosier Moms Cohort (NCT03696368) are collecting additional biomarkers which will enhance knowledge in this field. However implementing such measures in clinical practice, if they prove informative, could be complex and expensive and thus not suitable for use in all global contexts.

Our study has several limitations: Our reviews primarily relied on secondary analyses from observational studies that were not specifically designed to address the question of precision medicine in GDM treatment and were not powered for many of the comparisons made. Prior to introduction in clinical practice, any marker would have to be rigorously and prospectively tested with respect to sensitivity and specificity to predict treatment needs. The majority of data were extracted from clinical records leading to a lack of detail, such as the precise timing of BMI measurements, and limited information about whether BMI was self-reported or clinician measured. There was marked variation in approaches to GDM screening methods, choice of glucose challenge test and diagnostic thresholds. Whilst we included studies from a range of geographical settings, the majority of studies were from high income settings, and therefore our findings may not be applicable to low- and middle-income countries. Pregnancy outcomes of precision medicine strategies for GDM also remain unknown, underscoring the need for tailored interventions that account for patient perspective and diverse patient populations.

Despite these limitations, our study has several strengths. We used robust methods to identify a broad range of precision markers, many of which are routinely measured and can be easily translated into prediction models. We excluded studies where the choice of drug was decided by the clinician based on participant characteristics to avoid bias. Our study also highlights the need for further research in this area, particularly in exploring whether there are more sensitive markers that could be identified through “omics” approaches.

In conclusion, our findings suggest that precision medicine for GDM treatment holds promise as a tool to stream-line individuals towards the most effective and potentially cost-effective care. Whether this will impact on short-term pregnancy outcomes and longer term health outcomes for both mother and baby is not known. More research is urgently needed to identify precision lifestyle interventions and to explore whether more sensitive markers could be identified. Prospective studies, appropriately powered and designed to allow assessment of discriminative abilities

(sensitivity, specificity), and (external) validation studies are urgently needed to understand the utility and generalizability of our findings to under-represented populations. Consideration of how identified markers can be implemented feasibly and cost effectively in clinical practice is also required. Such efforts will be critical for realising the full potential of precision medicine and empowering patients and their health care providers to optimise short and long-term health outcomes for both mother and child.

Author contributions: All authors contributed to the design of the research questions, study selection, extraction of data, data analyses, quality assessment and data interpretation. RMR wrote the first draft of the manuscript. All authors edited the manuscript and all approved the final version.

Conflicts of Interest: None of the authors have any conflicts of interest to declare.

Funding: The ADA/EASD Precision Diabetes Medicine Initiative, within which this work was conducted, has received the following support: The Covidence license was funded by Lund University (Sweden) for which technical support was provided by Maria Björklund and Krister Aronsson (Faculty of Medicine Library, Lund University, Sweden). Administrative support was provided by Lund University (Malmö, Sweden), University of Chicago (IL, USA), and the American Diabetes Association (Washington D.C., USA). The Novo Nordisk Foundation (Hellerup, Denmark) provided grant support for in-person writing group meetings (PI: L Phillipson, University of Chicago, IL). JMM acknowledges the support of the Henry Friesen Professorship in Endocrinology, University of Manitoba, Canada. NMM and RMR acknowledge the support of the British Heart Foundation (RE/18/5/34216). SEO is supported by the Medical Research Council (MC_UU_00014/4) and British Heart Foundation (RG/17/12/33167).

REFERENCES

1. Saravanan, P. Gestational diabetes: opportunities for improving maternal and child health. *The Lancet. Diabetes & Endocrinology* **8**, 793-800 (2020).
2. Vounzoulaki, E., *et al.* Progression to type 2 diabetes in women with a known history of gestational diabetes: systematic review and meta-analysis. *BMJ* **369**, m1361 (2020).
3. Metzger, B.E., *et al.* Hyperglycemia and adverse pregnancy outcomes. *The New England Journal of Medicine* **358**, 1991-2002 (2008).
4. Crowther, C.A., *et al.* Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. *The New England Journal of Medicine* **352**, 2477-2486 (2005).
5. Powe, C.E., Hivert, M.F. & Udler, M.S. Defining Heterogeneity Among Women With Gestational Diabetes Mellitus. *Diabetes* **69**, 2064-2074 (2020).
6. Powe, C.E., *et al.* Heterogeneous Contribution of Insulin Sensitivity and Secretion Defects to Gestational Diabetes Mellitus. *Diabetes Care* **39**, 1052-1055 (2016).
7. Benhalima, K., *et al.* Characteristics and pregnancy outcomes across gestational diabetes mellitus subtypes based on insulin resistance. *Diabetologia* **62**, 2118-2128 (2019).
8. Madsen, L.R., *et al.* Do variations in insulin sensitivity and insulin secretion in pregnancy predict differences in obstetric and neonatal outcomes? *Diabetologia* **64**, 304-312 (2021).

9. Harrison, R.K., Cruz, M., Wong, A., Davitt, C. & Palatnik, A. The timing of initiation of pharmacotherapy for women with gestational diabetes mellitus. *BMC Pregnancy and Childbirth* **20**, 773 (2020).
10. Tisi, D.K., Burns, D.H., Luskey, G.W. & Koski, K.G. Fetal exposure to altered amniotic fluid glucose, insulin, and insulin-like growth factor-binding protein 1 occurs before screening for gestational diabetes mellitus. *Diabetes Care* **34**, 139-144 (2011).
11. Alvarez-Silvares, E., Bermúdez-González, M., Vilouta-Romero, M., García-Lavandeira, S. & Seoane-Pillado, T. Prediction of insulin therapy in women with gestational diabetes: a systematic review and meta-analysis of observational studies. *Journal of Perinatal Medicine* **50**, 608-619 (2022).
12. Dennis, J.M., Shields, B.M., Henley, W.E., Jones, A.G. & Hattersley, A.T. Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data. *The Lancet Diabetes & Endocrinology* **7**, 442-451 (2019).
13. Dawed, A.Y., *et al.* Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials. *The Lancet Diabetes & Endocrinology* **11**, 33-41 (2023).
14. Nolan, J.J., *et al.* ADA/EASD Precision Medicine in Diabetes Initiative: An International Perspective and Future Vision for Precision Medicine in Diabetes. *Diabetes Care* **45**, 261-266 (2022).
15. Franks, P.W. The Precision Medicine in Diabetes Initiative: 2nd International Consensus Report on Gaps & Opportunities for the Clinical Translation of Precision Diabetes Medicine. *Nature Medicine* (2023).
16. Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G. & Group, P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med* **151**, 264-269, W264 (2009).
17. Joanna Briggs Institute (JBI) critical appraisal tools <https://jbi.global/critical-appraisal-tools>. Accessed 15th April 2023
18. Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) <https://guidelines.diabetes.ca/cpg/chapter2>. Accessed 15th April 2023
19. Hedderson, M.M., *et al.* A Tailored Letter Based on Electronic Health Record Data Improves Gestational Weight Gain Among Women With Gestational Diabetes Mellitus: The Gestational Diabetes' Effects on Moms (GEM) Cluster-Randomized Controlled Trial. *Diabetes Care* **41**, 1370-1377 (2018).
20. Yew, T.W., *et al.* A Randomized Controlled Trial to Evaluate the Effects of a Smartphone Application-Based Lifestyle Coaching Program on Gestational Weight Gain, Glycemic Control, and Maternal and Neonatal Outcomes in Women With Gestational Diabetes Mellitus: The SMART-GDM Study. *Diabetes Care* **44**, 456-463 (2021).
21. Ares, J., *et al.* Gestational Diabetes Mellitus (GDM): Relationship Between Higher Cutoff Values for 100g Oral Glucose Tolerance Test (OGTT) and Insulin Requirement During Pregnancy. *Maternal and Child Health Journal* **21**, 1488-1492 (2017).
22. Barnes, R.A., *et al.* Predictors of large and small for gestational age birthweight in offspring of women with gestational diabetes mellitus. *Diabetic Medicine* **30**, 1040-1046 (2013).
23. Benhalima, K., *et al.* Differences in pregnancy outcomes and characteristics between insulin- and diet-treated women with gestational diabetes. *BMC Pregnancy and Childbirth* **15**, 271 (2015).
24. Berg, M., Adlerberth, A., Sultan, B., Wennergren, M. & Wallin, G. Early random capillary glucose level screening and multidisciplinary antenatal teamwork to improve outcome in gestational diabetes mellitus. *Acta Obstetrica et Gynecologica Scandinavica* **86**, 283-290 (2007).

25. Ducarme, G., *et al.* Predictive factors of subsequent insulin requirement for glycemic control during pregnancy at diagnosis of gestational diabetes mellitus. *International Journal of Gynaecology and Obstetrics* **144**, 265-270 (2019).
26. Durnwald, C.P., *et al.* Glycemic characteristics and neonatal outcomes of women treated for mild gestational diabetes. *Obstetrics and Gynecology* **117**, 819-827 (2011).
27. Elnour AA, M.J. Antenatal oral glucose-tolerance test values and pregnancy outcomes. *International Journal of Pharmacy Practice* **16**(3), 189-197 (2008).
28. Giannubilo, S.R., Pasculli, A., Ballatori, C., Biagini, A. & Ciavattini, A. Fetal Sex, Need for Insulin, and Perinatal Outcomes in Gestational Diabetes Mellitus: An Observational Cohort Study. *Clinical Therapeutics* **40**, 587-592 (2018).
29. Gibson, K.S., Waters, T.P. & Catalano, P.M. Maternal weight gain in women who develop gestational diabetes mellitus. *Obstetrics and Gynecology* **119**, 560-565 (2012).
30. Hillier, T.A., Ogasawara, K.K., Pedula, K.L. & Vesco, K.K. Markedly different rates of incident insulin treatment based on universal gestational diabetes mellitus screening in a diverse HMO population. *American Journal of Obstetrics and Gynecology* **209**, 440.e441-449 (2013).
31. Ikenoue, S., *et al.* Clinical impact of women with gestational diabetes mellitus by the new consensus criteria: two year experience in a single institution in Japan. *Endocrine Journal* **61**, 353-358 (2014).
32. Ito, Y., *et al.* Indicators of the need for insulin treatment and the effect of treatment for gestational diabetes on pregnancy outcomes in Japan. *Endocrine Journal* **63**, 231-237 (2016).
33. Kalok, A., *et al.* Correlation between Oral Glucose Tolerance Test Abnormalities and Adverse Pregnancy Outcomes in Gestational Diabetes: A Cross-Sectional Study. *International Journal of Environmental Research and Public Health* **17**(2020).
34. Koning, S.H., *et al.* Risk stratification for healthcare planning in women with gestational diabetes mellitus. *The Netherlands Journal of Medicine* **74**, 262-269 (2016).
35. Mecacci, F., *et al.* Different Gestational Diabetes Phenotypes: Which Insulin Regimen Fits Better? *Frontiers in Endocrinology* **12**, 630903 (2021).
36. Meghelli, L., Vambergue, A., Drumez, E. & Deruelle, P. Complications of pregnancy in morbidly obese patients: What is the impact of gestational diabetes mellitus? *Journal of Gynecology Obstetrics and Human Reproduction* **49**, 101628 (2020).
37. Molina-Vega, M., *et al.* Relationship between environmental temperature and the diagnosis and treatment of gestational diabetes mellitus: An observational retrospective study. *The Science of the Total Environment* **744**, 140994 (2020).
38. Ng, A., Liu, A. & Nanan, R. Association between insulin and post-caesarean resuscitation rates in infants of women with GDM: A retrospective study. *Journal of Diabetes* **12**, 151-157 (2020).
39. Nguyen, T.H., Yang, J.W., Mahone, M. & Godbout, A. Are There Benefits for Gestational Diabetes Mellitus in Treating Lower Levels of Hyperglycemia Than Standard Recommendations? *Canadian Journal of Diabetes* **40**, 548-554 (2016).
40. Nishikawa, T., *et al.* One-hour oral glucose tolerance test plasma glucose at gestational diabetes diagnosis is a common predictor of the need for insulin therapy in pregnancy and postpartum impaired glucose tolerance. *Journal of Diabetes Investigation* **9**, 1370-1377 (2018).
41. Ouzounian, J.G., *et al.* One-hour post-glucola results and pre-pregnancy body mass index are associated with the need for insulin therapy in women with gestational diabetes. *The Journal of Maternal-fetal & Neonatal Medicine* **24**, 718-722 (2011).
42. Parretti, S., *et al.* Gestational diabetes: A link between OGTT, maternal-fetal outcomes and maternal glucose tolerance after childbirth. *Nutrition, Metabolism, and Cardiovascular Diseases* **30**, 2389-2397 (2020).

43. Silva, J.K., Kaholokula, J.K., Ratner, R. & Mau, M. Ethnic differences in perinatal outcome of gestational diabetes mellitus. *Diabetes Care* **29**, 2058-2063 (2006).
44. Souza, A., *et al.* Can we stratify the risk for insulin need in women diagnosed early with gestational diabetes by fasting blood glucose? *The Journal of Maternal-fetal & Neonatal Medicine* **32**, 2036-2041 (2019).
45. Suhonen, L., Hiilesmaa, V., Kaaja, R. & Teramo, K. Detection of pregnancies with high risk of fetal macrosomia among women with gestational diabetes mellitus. *Acta Obstetrica et Gynecologica Scandinavica* **87**, 940-945 (2008).
46. Sun, T., *et al.* The effects of insulin therapy on maternal blood pressure and weight in women with gestational diabetes mellitus. *BMC Pregnancy and Childbirth* **21**, 657 (2021).
47. Wong, V.W. Gestational diabetes mellitus in five ethnic groups: a comparison of their clinical characteristics. *Diabetic Medicine* **29**, 366-371 (2012).
48. Wong, V.W. & Jalaludin, B. Gestational diabetes mellitus: who requires insulin therapy? *The Australian & New Zealand Journal of Obstetrics & Gynaecology* **51**, 432-436 (2011).
49. Zawiejska, A., Wender-Ozegowska, E., Radzicka, S. & Brazert, J. Maternal hyperglycemia according to IADPSG criteria as a predictor of perinatal complications in women with gestational diabetes: a retrospective observational study. *The Journal of Maternal-fetal & Neonatal Medicine* **27**, 1526-1530 (2014).
50. Bashir, M., *et al.* Metformin-treated-GDM has lower risk of macrosomia compared to diet-treated GDM- a retrospective cohort study. *The Journal of Maternal-fetal & Neonatal Medicine* **33**, 2366-2371 (2020).
51. Gilbert, L., *et al.* Mental health and its associations with glucose-lowering medication in women with gestational diabetes mellitus. A prospective clinical cohort study. *Psychoneuroendocrinology* **124**, 105095 (2021).
52. Krispin, E., Ashkenazi Katz, A., Shmuel, E., Toledano, Y. & Hadar, E. Characterization of women with gestational diabetes who failed to achieve glycemic control by lifestyle modifications. *Archives of Gynecology and Obstetrics* **303**, 677-683 (2021).
53. Meshel, S., *et al.* Can we predict the need for pharmacological treatment according to demographic and clinical characteristics in gestational diabetes? *The Journal of Maternal-fetal & Neonatal Medicine* **29**, 2062-2066 (2016).
54. Zhu, S., Meehan, T., Veerasingham, M. & Sivanesan, K. COVID-19 pandemic gestational diabetes screening guidelines: A retrospective study in Australian women. *Diabetes & Metabolic Syndrome* **15**, 391-395 (2021).
55. Chmait, R., Dinise, T. & Moore, T. Prospective observational study to establish predictors of glyburide success in women with gestational diabetes mellitus. *Journal of Perinatology* **24**, 617-622 (2004).
56. Conway, D.L., Gonzales, O. & Skiver, D. Use of glyburide for the treatment of gestational diabetes: the San Antonio experience. *The Journal of Maternal-fetal & Neonatal Medicine* **15**, 51-55 (2004).
57. Harper, L.M., Glover, A.V., Biggio, J.R. & Tita, A. Predicting failure of glyburide therapy in gestational diabetes. *Journal of Perinatology* **36**, 347-351 (2016).
58. Kahn, B.F., Davies, J.K., Lynch, A.M., Reynolds, R.M. & Barbour, L.A. Predictors of glyburide failure in the treatment of gestational diabetes. *Obstetrics and Gynecology* **107**, 1303-1309 (2006).
59. Rochon, M., Rand, L., Roth, L. & Gaddipati, S. Glyburide for the management of gestational diabetes: risk factors predictive of failure and associated pregnancy outcomes. *American Journal of Obstetrics and Gynecology* **195**, 1090-1094 (2006).
60. Yogeve, Y., *et al.* Glyburide in gestational diabetes--prediction of treatment failure. *The Journal of Maternal-fetal & Neonatal Medicine* **24**, 842-846 (2011).

61. Gante, I., Melo, L., Dores, J., Ruas, L. & Almeida, M.D.C. Metformin in gestational diabetes mellitus: predictors of poor response. *European Journal of Endocrinology* **178**, 129-135 (2018).
62. Khin, M.O., Gates, S. & Saravanan, P. Predictors of metformin failure in gestational diabetes mellitus (GDM). *Diabetes & Metabolic Syndrome* **12**, 405-410 (2018).
63. McGrath, R.T., Glastras, S.J., Hocking, S. & Fulcher, G.R. Use of metformin earlier in pregnancy predicts supplemental insulin therapy in women with gestational diabetes. *Diabetes Research and Clinical Practice* **116**, 96-99 (2016).
64. Picón-César, M.J., *et al.* Metformin for gestational diabetes study: metformin vs insulin in gestational diabetes: glycemic control and obstetrical and perinatal outcomes: randomized prospective trial. *American Journal of Obstetrics and Gynecology* **225**, 517.e511-517.e517 (2021).
65. Rowan, J.A., Hague, W.M., Gao, W., Battin, M.R. & Moore, M.P. Metformin versus insulin for the treatment of gestational diabetes. *The New England Journal of Medicine* **358**, 2003-2015 (2008).
66. Terti, K., Ekblad, U., Koskinen, P., Vahlberg, T. & Rönnekaa, T. Metformin vs. insulin in gestational diabetes. A randomized study characterizing metformin patients needing additional insulin. *Diabetes, Obesity & Metabolism* **15**, 246-251 (2013).
67. Bouchghoul, H., *et al.* Hypoglycemia and Glycemic Control With Glyburide in Women With Gestational Diabetes and Genetic Variants of Cytochrome P450 2C9 and/or OATP1B3. *Clinical Pharmacology and Therapeutics* **110**, 141-148 (2021).
68. Huhtala, M.S., Terti, K. & Rönnekaa, T. Serum lipids and their association with birth weight in metformin and insulin treated patients with gestational diabetes. *Diabetes Research and Clinical Practice* **170**, 108456 (2020).
69. Ayman, G., *et al.* The top 10 research priorities in diabetes and pregnancy according to women, support networks and healthcare professionals. *Diabetic Medicine* **38**, e14588 (2021).
70. Cooray, S.D., *et al.* Development, validation and clinical utility of a risk prediction model for adverse pregnancy outcomes in women with gestational diabetes: The PeRSONal GDM model. *EClinicalMedicine* **52**, 101637 (2022).
71. Liao, L.D., *et al.* Development and validation of prediction models for gestational diabetes treatment modality using supervised machine learning: a population-based cohort study. *BMC Medicine* **20**, 307 (2022).
72. Cassinelli, E.H., *et al.* Preconception health and care policies and guidelines in the UK and Ireland: a scoping review. *Lancet* **400 Suppl 1**, S61 (2022).
73. Hjorth, M.F., *et al.* Pretreatment Fasting Glucose and Insulin as Determinants of Weight Loss on Diets Varying in Macronutrients and Dietary Fibers-The POUNDS LOST Study. *Nutrients* **11**(2019).
74. Hjorth, M.F., *et al.* Pretreatment fasting plasma glucose and insulin modify dietary weight loss success: results from 3 randomized clinical trials. *The American Journal of Clinical Nutrition* **106**, 499-505 (2017).
75. Hjorth, M.F., Due, A., Larsen, T.M. & Astrup, A. Pretreatment Fasting Plasma Glucose Modifies Dietary Weight Loss Maintenance Success: Results from a Stratified RCT. *Obesity* **25**, 2045-2048 (2017).
76. Bergia, R.E., *et al.* Differential Glycemic Effects of Low- versus High-Glycemic Index Mediterranean-Style Eating Patterns in Adults at Risk for Type 2 Diabetes: The MEDGI-Carb Randomized Controlled Trial. *Nutrients* **14**(2022).
77. Aldubayan, M.A., *et al.* A double-blinded, randomized, parallel intervention to evaluate biomarker-based nutrition plans for weight loss: The PREVENTOMICS study. *Clinical Nutrition* **41**, 1834-1844 (2022).

78. Trouwborst, I., *et al.* Cardiometabolic health improvements upon dietary intervention are driven by tissue-specific insulin resistance phenotype: A precision nutrition trial. *Cell Metabolism* **35**, 71-83.e75 (2023).
79. Cifuentes, L., *et al.* Phenotype tailored lifestyle intervention on weight loss and cardiometabolic risk factors in adults with obesity: a single-centre, non-randomised, proof-of-concept study. *EClinicalMedicine* **58**, 101923 (2023).

Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagrams for the two systematics reviews: **A)** behavioural (diet and lifestyle) interventions and **B)** pharmacological interventions.

Figure 1A. Behavioural (diet and lifestyle) interventions




Figure 1B. Pharmacological interventions




Figure 2.1 Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all studies included in the meta-analyses.




Figure 2.2 Risk of bias summary: review authors' judgements about each risk of bias item for each study included in the meta-analyses.

Study	Did the author(s) describe how a diagnose of GDM was assigned?	Did the author(s) define inclusion/exclusion criteria?	Did all women receive standard of care?	Is there a description for pharmacologic therapy initiation protocol?	Were the outcomes (i.e., precision markers) measured in a valid and reliable way?
Ares 2017	+	+	+	+	+
Barnes 2013	+	+	+	+	+
Bashir 2020	+	+	+	+	+
Benhalima 2015	+	+	+	+	+
Chenat 2004	+	+	+	+	+
Conway 2004	+	+	+	+	+
Ducarme 2019	+	+	+	+	+
Durmald 2011	+	+	+	+	+
Garre 2018	+	+	+	+	+
Gilbert 2021	+	+	+	+	+
Harper 2016	+	+	+	+	+
Ikeroue 2014	+	+	+	+	+
Itto 2016	+	+	+	+	+
Kahn 2006	+	+	+	+	+
Kalok 2020	+	+	+	+	+
Khin 2018	+	+	+	+	+
Koning 2016	+	+	+	+	+
Krispin 2021	+	+	+	+	+
McGrath 2016	+	+	+	+	+
Meccardi 2021	+	+	+	+	+
Mejhalli 2020	+	+	+	+	+
Meskel 2016	+	+	+	+	+
Ng 2020	+	+	+	+	+
Nishikawa 2018	+	+	+	+	+
Olzounian 2011	+	+	+	+	+
Pedón-César 2021	+	+	+	+	+
Rochon 2006	+	+	+	+	+
Roman 2008	+	+	+	+	+
Souza 2019	+	+	+	+	+
Suomen 2008	+	+	+	+	+
Sun 2021	+	+	+	+	+
Tertti 2013	+	+	+	+	+
Wong 2011	+	+	+	+	+
Yogev 2011	+	+	+	+	+

Tables 1A and 1B Summary of included studies in the two systematic reviews

Table 1A Precision behavioural (diet and lifestyle) interventions

First Author Year	Study Name	Country	Population	Intervention	Precision Marker	GDM Diagnostic Criteria	Sample Size
^b Hedderson 2018 ¹⁹	GEM Study	USA	Pregnant, age 18+, GDM	Receiving a tailored letter with messages regarding weight	Pregnancy BMI category	Carpenter Coustan	n control =1047 n intervention=967
^b Yew 2021 ²⁰	SMART-GDM Study	Singapore	Pregnant, age 21+, singleton, GDM	Web/Smart phone lifestyle coaching program	Gestational weight gain at study entry	WHO 2013 criteria (12-30 weeks)	n control = 170 n intervention= 170

GDM, gestational diabetes; BMI, body mass index; WHO, World Health Organization

Table 1B. Precision predictors of need for pharmacological interventions to achieve target glucose levels

*First Author Year	Study Design and Name	Country	Population	GDM Diagnostic Test Criteria	Sample Size	Precision Marker(s)
Medical therapy required to achieve target glucose levels in addition to standard care with diet and lifestyle advice						
<i>Insulin required when diet not adequate</i>						
^a Ares 2017 ²¹	Retrospective cohort study	Spain	Pregnant, GDM, singleton pregnancy, no malformations	100g 3h OGTT	Total in analysis N = 201 N (%) diet not adequate N = 36 (18)	age, BMI, OGTT glucose values
^a Barnes 2013 ²²	Retrospective cohort study	Australia	Pregnant, GDM, singleton pregnancy	ADIPS criteria	Total in analysis N = 1695 N (%)diet not adequate N = 524 (30.9)	Pre-pregnancy BMI, total maternal GWG, HbA1c at GDM diagnosis

^a Benhalima 2015 ²³	Retrospective cohort study	Belgium	Pregnant, GDM	50g GCT and 100g 3h OGTT, Carpenter and Coustan	Total in analysis N = 601 N (%) diet not adequate N = 145 (24.1)	age, GA at delivery, BMI at first prenatal visit, ethnicity, family history of GDM, history of GDM, parity, results of OGTT and GCT, GA at GDM diagnosis and at GDM screening, insulin sensitivity and beta cell function
^b Berg 2007 ²⁴	Retrospective cohort study	Sweden	Pregnant, GDM.	75g OGTT, 1998 WHO classification criteria	Total in analysis N = 719 N (%) diet not adequate N = 112 (15.6)	BMI
^a Ducarme 2019 ²⁵	Prospective observational study	France	Pregnant, GDM, singleton pregnancy.	75g OGTT	Total in analysis N = 200 N (%) diet not adequate N = 72 (36.0)	age, pre pregnancy BMI, obesity, overweight, parity, previous >4kg baby, previous GDM, glucose values in OGTT, fructosamine, HbA1c
^a Durnwald 2011 ²⁶	Secondary analyses of RCT	USA	Pregnant, Women with mild GDM, who were randomized to dietary intervention in prospective RCT	fasting glucose less than 95 mg/dL and at least two of three glucose values that met or exceeded the following: 1-hour of 180 mg/dL, 2-hour 155 mg/dL, 3-hour 140 mg/dL	Total in analysis N = 460 N (%) diet not adequate N = 36 (7.8)	age, GWG, ethnicity, smoking, alcohol, BMI at enrollment, 50-g glucose screening value
^b Elmour 2008 ²⁷	Observational, cohort study, within RCT	United Arab Emirates	Pregnant, Women with	100g, 3h OGTT, National Diabetes Data Group and	Total in analysis N = 165	OGTT values

			GDM, UAE national	Carpenter & Coustan	N (%) diet not adequate N = 91 (55.1)	
^b Giannubilo 2018 ²⁸	Prospective observational cohort study	Italy	Pregnant, GDM, singleton pregnancy, European, primiparous, non-smoking	100g, 3h OGTT, Carpenter & Coustan	Total in analysis N = 327 N (%) diet not adequate N = 133 (40.6)	Offspring sex
^b Gibson 2012 ²⁹	Case-control (1:3) study	USA	Pregnant, GDM, singleton pregnancy, no malformations	50g GCT and 100g OGTT, Carpenter & Coustan	Total in analysis N = 163 N (%) diet not adequate N = not recorded	GWG by 24 weeks GA, pre-pregnancy BMI, glucose values
^b Hillier 2013 ³⁰	Population-based epidemiology study	USA	Pregnant, GDM, singleton pregnancy	Carpenter & Coustan	Total in analysis N = 1326 N (%) diet not adequate N = 158 (11.9)	BMI group, ethnicity, GA at diagnosis
^a Ikenoue 2014 ³¹	Retrospective cohort study	Japan	Pregnant, GDM, singleton pregnancy, no malformations	50g GCT and diagnostic 75g OGTT, IADPSG criteria	Total in analysis N = 141 N (%) diet not adequate N = 50 (35.5)	Age, BMI, GCT & OGTT values, family history, GA at diagnosis, HbA1C, Insulin sensitivity
^a Ito 2016 ³²	Retrospective cohort study	Japan	Pregnant, GDM	Risk factors – 75g OGTT; no risk factors 2-step GCT and 75g OGTT, IADPSG criteria	Total in analysis N = 102 N (%) diet not adequate N = 32 (31.4)	Age, GA at GDM diagnosis, BMI at diagnosis, family history of diabetes, prior fetal macrosomia, results of OGTT, glycoalbumin, daily calories at diagnosis, plasma glucose profile

^a Kalok 2020 ³³	Retrospective cohort study	Malaysia	Pregnant, GDM, singleton pregnancy	75g OGTT NICE guideline (fasting glucose \geq 5.6 mmol/L and/or 2h post glucose load \geq 7.8 mmol/L)	Total in analysis N = 1064 N (%) diet not adequate N = 96 (9)	Age, GA at GDM diagnosis, trimester of pregnancy at diagnosis, OGTT glucose values, family history of diabetes, previous GDM, obesity
^a Koning 2016 ³⁴	Retrospective cohort study	Netherlands	Pregnant, GDM, singleton pregnancy	75g OGTT, WHO 1999, FPG \geq 7.0 mmol/l and/or the 2h plasma glucose \geq 7.8 mmol/l	Total in analysis N = 820 N (%) diet not adequate N = 360 (44)	Age, family history of diabetes, previous GDM, previous infant weighing >4500g, history of intrauterine death, parity, pre-pregnancy BMI, GWG, glucose levels in OGTT, Hba1c
^a Mecacci 2021 ³⁵	Retrospective cohort study	Italy	Pregnant, GDM, singleton pregnancy	IADPSG	Total in analysis N = 1974 N (%) diet not adequate N = 1012 (51.3)	Age, pre-pregnancy BMI, family history of diabetes, previous GDM, FPG, hypothyroidism, and assisted reproductive technologies
^a Meghelli 2020 ³⁶	Retrospective cohort study	France	Pregnant, GDM, pre-pregnancy BMI \geq 40	1999-2009 O'sullivan's test (2-step); after that IADPSG	Total in analysis N = 121 N (%) diet not adequate N = 63 (52.9)	Age, BMI, parity, history of C-section, history of gestational HTN, history of GDM, smoking, GWG
^b Molina-Vega 2020 ³⁷	Retrospective cohort study	Spain	Pregnant, GDM	2 step 50g GCT and 75g OGTT, National Diabetes Data Group criteria	Total in analysis N = 473 N (%) diet not adequate N = 129 (27.3)	Age, BMI, Season
^a Ng 2020 ³⁸	Retrospective cohort study	Australia	Pregnant, GDM, singleton	ADIPS 75g OGTT - \geq 5.5, 2-h \geq 8.0	Total in analysis N = 1857	Age, BMI, alcohol consumption, smoking

			pregnancy, ≥ 37 weeks GA at birth		N (%) diet not adequate N = 576 (31.02)	history, pre-eclampsia, alcohol
^b Nguyen 2016 ³⁹	Retrospective cohort study	Canada	Pregnant, GDM	Local Montreal criteria - 75g OGTT FPG ≥ 5.0 mmol/L or 2-hour post-OGTT glucose ≥ 7.8 mmol/L	Total in analysis N = 1827 N (%) diet not adequate N = 1056 (57.8)	Glucose values, pre-pregnancy BMI, GWG, previous C-section, history of macrosomia, previous GDM
^a Nishikawa 2018 ⁴⁰	Retrospective cohort study	Japan	Pregnant, GDM	50g GCT (>140 mg/dL), IADPSG for 75g OGTT	Total in analysis N = 529 N (%) diet not adequate N = 57 (11)	GA at GDM diagnosis, history of pregnancy, family history of DM, pre-pregnancy BMI, OGTT values, HbA1c
^a Ouzounian 2011 ⁴¹	Retrospective cohort study	USA	Pregnant, GDM, , singleton pregnancy, liveborn fetus, ≥ 37 weeks GA at birth	1h plasma glucose post 50g >200 or ADA criteria for 3h OGTT	Total in analysis N = 1451 N (%) diet not adequate N = 262 (18.1)	maternal age, multiparity, ethnicity, prenatal care in 1st trimester, BMI category, prior GDM, history of macrosomia, history of stillbirth, OGTT values
^b Parrettini 2020 ⁴²	Retrospective cohort study	Italy	Pregnant, GDM, singleton pregnancy, age ≥ 18 years	IADPSG	Total in analysis N = 602 N (%) diet not adequate N = 390 (64.8)	Maternal age, OGTT results
^a Silva 2006 ⁴³	Retrospective cohort study	USA	Pregnant, GDM	Carpenter & Coustan	Total in analysis N = 2155 N (%) diet not adequate N = 427 (19.8)	Ethnicity
^a Souza 2019 ⁴⁴	Retrospective cohort study	Brazil	Pregnant, GDM, singleton pregnancy	IADPSG	Total in analysis N = 408	age, parity, pre-pregnancy (BMI), GWG, smoking

^a Chmait 2004 ⁵⁵	Retrospective cohort study	USA	Pregnant, GDM, glyburide treated but requiring supplemental insulin therapy to meet glycaemic targets	1 hour, 50 g oral glucose challenge followed by 100g OGTT Carpenter and Coustan's criteria	Total in analysis N = 69 N (%) glyburide not adequate N = 13 (18.8%)	GA at GDM diagnosis and at glyburide initiation, fasting and 1 hour postprandial glucose
^a Conway 2004 ⁵⁶	Retrospective cohort study	USA	Pregnant, GDM, glyburide treated but requiring supplemental insulin therapy to meet glycaemic targets	ADA guidelines	Total in analysis N = 75 N (%) glyburide not adequate N = 12 (16%)	glucose values, GA at glyburide initiation
^a Harper 2016 ⁵⁷	Retrospective cohort study	USA	Pregnant, GDM, glyburide treated but requiring supplemental insulin therapy to meet glycaemic targets	1 hour glucose tolerance test followed by 3 hour glucose tolerance Carpenter and Coustan's criteria	Total in analysis N = 63 N (%) glyburide not adequate N = 63 (17.5%)	previous GDM, GA at GDM diagnosis, glucose values
^a Kahn 2006 ⁵⁸	Retrospective cohort study	USA	Pregnant, GDM, glyburide treated but requiring supplemental insulin therapy to meet glycaemic targets	1 hour, 50 g oral glucose challenge followed by 100g OGTT Carpenter and Coustan's criteria	Total in analysis N = 95 N (%) glyburide not adequate N = 18 (19%)	age, GA of diagnosis of GDM, gravidity, parity, glucose values
^a Rochon 2006 ⁵⁹	Retrospective cohort study	USA	Pregnant, GDM, glyburide treated but requiring supplemental insulin therapy to meet glycaemic targets	1 hour, 50 g oral glucose challenge followed by 100g OGTT Carpenter and Coustan's criteria	Total in analysis N = 101 N (%) glyburide not adequate N = 21 (20.8%)	age, parity, BMI, family history of diabetes, Previous GDM, glucose values

^a Yogev 2011 ⁶⁰	Retrospective cohort study	Israel	Pregnant, GDM, glyburide treated but requiring supplemental insulin therapy to meet glycaemic targets	1 hour, 50 g oral glucose challenge followed by 100g OGTT Carpenter and Coustan's criteria	Total in analysis N = 124 N (%) glyburide not adequate 31 (25%)	previous GDM, glucose values and GWG
<i>Metformin not adequate</i>						
^a Gante 2018 ⁶¹	Retrospective cohort study	Portugal	Pregnant, GDM, metformin treated but requiring supplemental insulin therapy to meet glycaemic targets	Portuguese Directorate-General of Health (Direção Geral de Saúde) criteria based on IADPSG criteria	Total in analysis N = 388 N (%) metformin not adequate N = 135 (34.8%)	age, pre-pregnancy BMI, earlier introduction of metformin
^a Khin 2018 ⁶²	Retrospective cohort study	UK	Pregnant, GDM, metformin treated but requiring supplemental insulin therapy to meet glycaemic targets	75 g OGTT between 24-28 weeks of gestation with fasting levels of 6.1 mmol/l and/or 2 h postprandial 7.8 mmol/l	Total in analysis N = 138 N (%) metformin not adequate N = 77 (55.8%)	age, fasting glucose level and HbA1c at OGTT, GA at medication initiation
^a McGrath 2016 ⁶³	Retrospective cohort study	Australia	Pregnant, GDM, metformin treated but requiring supplemental insulin therapy to meet glycaemic targets	not given	Total in analysis N = 53 N (%) metformin not adequate N = 34 (54%)	GA at metformin initiation
^a Picón-César 2021 ⁶⁴	RCT metformin for GDM trial	Spain	Pregnant, GDM, singleton pregnancy, age 18-45 years, GA 14-35 weeks, met criteria for medical therapy,	50-gram oral glucose screening (O'Sullivan test) followed by a 100-gram OGTT using the National Diabetes Data	Total in analysis N = 90 N (%) metformin not adequate N = 20 (22.3%)	previous GDM, GA at randomisation, glucose values in the OGTT, SBGM at randomization

			randomized to metformin but required subsequent insulin therapy	Group criteria. Isolated fasting glycaemia at 100 mg/dL (5.6 mmol/L) was also considered as GDM		
^a Rowan 2008 ⁶⁵	RCT Metformin in Gestational Diabetes (MIG) Trial	Australia and New Zealand	Pregnant, GDM, singleton pregnancy, age 18-45 years, met criteria for medical therapy, randomized to metformin but required subsequent insulin therapy	75 g OGTT Australasian Diabetes in Pregnancy Society criteria	Total in analysis N = 363 N (%) metformin not adequate N = 168 (46.3%)	BMI, glucose values
^a Tertti 2013*** ⁶⁶	RCT comparing metformin vs. insulin	Finland	Pregnant, GDM, singleton pregnancy, met criteria for medical therapy, randomized to metformin but required subsequent insulin therapy	75 g OGTT determined by Finnish national criteria. The diagnostic cutoff values of plasma glucose up to December 2008 were: fasting ≥ 4.8 mmol/l, 1 h ≥ 10.0 mmol/l and 2 h ≥ 8.7 mmol/l, and thereafter ≥ 5.3 , ≥ 10.0 and ≥ 8.6 mmol/l, respectively	Total in analysis n = 110 N (%) metformin not adequate N = 23 (20.9%)	age, GA at OGTT and randomisation, HbA1c, fructosamine
Others						
^b Bouchghou I 2021 ⁶⁷	Observational study of a subset of the	France	Pregnant, GDM, met criteria for medical therapy	not given, other than diagnosed between	Total in analysis N = 117	CYP2C9 and OATP1B3 genetic polymorphisms

	Insulin Daonil trial (INDAO) participants of randomization to glyburide vs. insulin		and randomized to glyburide	24-34 weeks gestation	N (%) glyburide not adequate: 7/54 (13.0%) in wild type group, 8/42 (19.0%) in intermediate group, 5/21 (23.8%) in variant group	
^b Huhtala 2020*** ⁶⁸	Secondary analysis of data from RCT comparing metformin vs. insulin	Finland	Pregnant, GDM, singleton pregnancy, met criteria for medical therapy	75 g OGTT determined by Finnish national criteria (as above)	N = 100-108 Metformin treated; N = 95-107 Insulin treated	maternal lipidome responses to metformin and insulin

ADA, American Diabetes Association; ADIPS, Australian Diabetes in Pregnancy Society; BMI, body mass index; FPG, fasting plasma glucose; GA, gestational age; GCT, glucose challenge test; GDM, gestational diabetes; GWG, gestational weight gain; HbA1c, glycosylated haemoglobin; HTN, hypertension; IADPSG, International Association of Diabetes and Pregnancy Study Group; OGTT, oral glucose tolerance test; RCT, randomized controlled trial; SBGM, self blood glucose monitoring

*Studies in each subgroup listed in alphabetical order of first author

^a Studies included in meta-analyses

^b Studies included in narrative synthesis

**Wong 2011 and 2012 contain overlapping data

***Huhtala 2020 is secondary analyses of Tertti 2013

Table 2. Lifestyle adequate to achieve target glucose levels vs not adequate

Precision Marker	Studies	Participants	Statistical Method	Effect Estimate (95%CI)	GRADE
Age	20	14620	Mean difference (95%CI)	-0.98 [-1.23, -0.73]	⊕⊕○○
Nulliparity	8	6969	Odds Ratio (95%CI)	1.53 [1.23, 1.89]	⊕⊕○○
Body mass index	16	11313	Mean difference (95%CI)	-1.83 [-2.32, -1.35]	⊕⊕○○
Previous history of GDM	13	9885	Odds Ratio (95%CI)	0.46 [0.37, 0.57]	⊕⊕○○
Haemoglobin A1C	8	4825	Mean difference (95%CI)	-0.21 [-0.27, -0.14]	⊕⊕○○
Fasting glucose	13	8663	Mean difference (95%CI)	-6.26 [-8.44, -4.08]	⊕⊕○○
1-hour glucose	10	6579	Mean difference (95%CI)	-15.33 [-20.81, -9.85]	⊕○○○
2-hour glucose	12	8255	Mean difference (95%CI)	-9.06 [-13.55, -4.56]	⊕○○○
3-hour glucose	3	2126	Mean difference (95%CI)	-8.56 [-12.58, -4.54]	⊕○○○
Family history of diabetes	13	9256	Odds Ratio (95%CI)	0.66 [0.59, 0.75]	⊕⊕○○
Gestational age at GDM diagnosis	9	5882	Mean difference (95%CI)	3.06 [2.33, 3.79]	⊕⊕○○
Smoking history	5	3488	Odds Ratio (95%CI)	0.80 [0.52, 1.23]	⊕⊕○○
Previous history of macrosomia	7	5595	Odds Ratio (95%CI)	0.63 [0.42, 0.94]	⊕⊕○○

Very low ⊕○○○

Low ⊕⊕○○

Table 3. Oral pharmacological agent adequate to achieve target glucose levels vs not adequate

Precision Marker	Studies	Participants	Statistical Method	Effect Estimate (95%CI)	GRADE
Age	11	1473	Mean difference (95%CI)	-1.04 [-2.10, 0.03]	⊕⊕○○
Nulliparity	8	1215	Odds Ratio (95%CI)	1.55 [1.17, 2.04]	⊕⊕○○
Body mass index	10	1692	Mean difference (95%CI)	-1.21 [-2.21, -0.21]	⊕⊕○○
Previous history of GDM	8	1412	Odds Ratio (95%CI)	0.43 [0.30, 0.63]	⊕⊕○○
Haemoglobin A1C	6	1152	Mean difference (95%CI)	-0.21 [-0.29, -0.13]	⊕⊕○○
Fasting glucose	12	1836	Mean difference (95%CI)	-8.02 [-11.87, -4.16]	⊕○○○
1-hour glucose	8	1177	Mean difference (95%CI)	-10.64 [-18.25, -3.02]	⊕○○○
2-hour glucose	10	1378	Mean difference (95%CI)	-7.31 [-11.38, -3.25]	⊕○○○
3-hour glucose	6	679	Mean difference (95%CI)	0.00 [-11.79, 11.79]	⊕○○○
Family history of diabetes	6	1040	Odds Ratio (95%CI)	0.79 [0.50, 1.25]	⊕⊕○○
Gestational age at GDM diagnosis	11	1473	Mean difference (95%CI)	2.64 [1.42, 3.86]	⊕⊕○○
Gestation at oral pharmacological agent initiation	7	967	Mean difference (95%CI)	3.79 [2.08, 5.51]	⊕⊕○○

Very low ⊕○○○

Low ⊕⊕○○